• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immunovant Inc.

    4/15/24 4:16:37 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMVT alert in real time by email
    S-8 1 d827268ds8.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on April 15, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IMMUNOVANT, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-2771572
    (State of incorporation or organization)   (I.R.S. Employer Identification No.)

    320 West 37th Street

    New York, NY

      10018
    (Address of principal executive office)   (Zip Code)

    Immunovant, Inc. 2019 Equity Incentive Plan

    (Full title of the plan)

    Eva Renee Barnett

    Chief Financial Officer

    Immunovant, Inc.

    320 West 37th Street

    New York, NY 10018

    (917) 580-3099

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

    Marc Recht

    Brandon Fenn

    Cooley LLP

    500 Boylston Street, 14th Floor

    Boston, MA 02116

    (617) 937-2300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    We are filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “SEC”) for the purpose of registering an additional 5,823,319 shares of our common stock (“Common Stock”) under the 2019 Equity Incentive Plan, which shares of Common Stock are in addition to the shares of Common Stock registered on our Registration Statements on Form S-8 (File Nos. 333-236665, 333-239537, 333-262087, 333-265477 and 333-271138), filed with the SEC on February 26, 2020, June 29, 2020, January 10, 2022, June 8, 2022, and April 5, 2023, respectively (the “Prior Forms S-8”). In accordance with the instructional note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    PART II

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Forms S-8 are incorporated by reference herein. In addition, the following documents we filed with the SEC are incorporated by reference into this Registration Statement:

    (a) Our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 (the “Annual Report”), filed with the Commission on May 22, 2023;

    (b) Our Quarterly Reports on Form 10-Q for the quarterly period ended June 30, 2023, filed with the SEC on August  10, 2023, for the quarterly period ended September 30, 2023, filed with the SEC on November  9, 2023 and for the quarterly period ended December  31, 2023, filed with the SEC on February 12, 2024;

    (c) the information specifically incorporated by reference in our Annual Report on Form 10-K for the year ended March  31, 2023 from our definitive proxy statement relating to our 2023 annual meeting of stockholders, filed with the SEC on June 26, 2023;

    (d) Our Current Reports on Form 8-K filed with the SEC on May  22, 2023 (only with respect to information filed under item 8.01), August 22, 2023, September  26, 2023 (only with respect to information filed under item 8.01), September  28, 2023, November  28, 2023 (only with respect to information filed under item 8.01) and December 20, 2023 (only with respect to information filed under item 8.01);

    (e) The description of the Common Stock, which is contained in our Registration Statement on Form 8-A, filed with the SEC on May 9, 2019 (File No. 001-38906) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description; and

    All documents, reports and definitive proxy or information statements filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 8. EXHIBITS.

     

              Incorporated by Reference  

    Exhibit

    Number

      

    Description

       Schedule
    Form
         File Number      Exhibit      Filing Date  
    4.1    Amended and Restated Certificate of Incorporation of Immunovant, Inc.      8-K        001-38906        3.1        December 20, 2019  
    4.2    Amended and Restated Bylaws of Immunovant, Inc.      8-K        001-38906        3.2        December 20, 2019  
    5.1*    Opinion of Cooley LLP.            
    23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm.            
    23.3*    Consent of Cooley LLP (included in Exhibit 5.1).            
    24.1*    Power of Attorney (included on the signature page of this Form S-8).            
    99.1    2019 Equity Incentive Plan.      10-K        001-38906        10.3        June 29, 2020  
    99.2    Forms of Option Grant Notices and Option Agreements under 2019 Equity Incentive Plan.      10-K        001-38906        10.3.1        June 29, 2020  
    99.3    Forms of Restricted Stock Unit Grant Notices and Award Agreements under 2019 Equity Incentive Plan.      10-K        001-38906        10.3.2        June 29, 2020  
    99.4    UK Sub-Plan to the Immunovant, Inc. 2019 Equity Incentive Plan      10-Q        001-38906        10.1        February 3, 2023  
    99.5    Form of Stock Option Grant Notice and Agreement for the UK Sub-Plan      10-Q        001-38906        10.2        February 3, 2023  
    99.6    Form of Restricted Stock Unit Grant Notice and Agreement for the UK Sub-Plan      10-Q        001-38906        10.3        February 3, 2023  
    107*    Filing Fee Table            

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on this 15th day of April, 2024.

     

    IMMUNOVANT, INC.
    By:  

    /S/ PETER SALZMANN

      Peter Salzmann, M.D., M.B.A.
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter Salzmann, M.D. and Eva Renee Barnett, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ PETER SALZMANN

    Peter Salzmann, M.D., M.B.A.

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

       April 15, 2024

    /s/ EVA RENEE BARNETT

    Eva Renee Barnett

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

       April 15, 2024

    /s/ FRANK M. TORTI

    Frank M. Torti, M.D.

       Executive Chairperson of the Board of Directors    April 15, 2024

    /s/ ANDREW FROMKIN

    Andrew Fromkin

       Director    April 15, 2024

    /s/ DOUGLAS HUGHES

    Douglas Hughes

       Director    April 15, 2024

    /s/ GEORGE MIGAUSKY

    George Migausky

       Director    April 15, 2024

    /s/ ATUL PANDE

    Atul Pande, M.D.

       Director    April 15, 2024

    /s/ ERIC VENKER

    Eric Venker, M.D., Pharm.D.

       Director    April 15, 2024
    Get the next $IMVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMVT

    DatePrice TargetRatingAnalyst
    1/6/2026$50.00Peer Perform → Outperform
    Wolfe Research
    10/14/2025$16.00Hold
    Truist
    7/10/2025$18.00Neutral
    Goldman
    3/3/2025$20.00Hold
    Jefferies
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    10/10/2024$36.00Outperform
    Raymond James
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    3/28/2024$50.00Outperform
    Oppenheimer
    More analyst ratings

    $IMVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Stout Jay S sold $51,461 worth of shares (1,977 units at $26.03), decreasing direct ownership by 0.99% to 197,634 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    1/23/26 4:21:29 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Technology Officer Stout Jay S sold $31,914 worth of shares (1,203 units at $26.53), decreasing direct ownership by 0.60% to 199,611 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    1/9/26 4:03:09 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Van Tuyl Christopher sold $290,943 worth of shares (10,813 units at $26.91), decreasing direct ownership by 7% to 149,930 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/19/25 4:05:25 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

    IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

    2/6/26 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

    DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,

    1/23/26 5:25:47 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunovant Announces Pricing of $550 Million Common Stock Financing

    Funding to provide runway through potential Graves' Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company's controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Imm

    12/11/25 1:29:26 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immunovant Sciences upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Immunovant Sciences from Peer Perform to Outperform and set a new price target of $50.00

    1/6/26 8:39:27 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Immunovant Sciences with a new price target

    Truist initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $16.00

    10/14/25 8:50:33 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on Immunovant Sciences with a new price target

    Goldman resumed coverage of Immunovant Sciences with a rating of Neutral and set a new price target of $18.00

    7/10/25 8:56:07 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/12/25 5:17:21 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    1/15/25 4:36:38 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    10/4/23 5:15:20 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    SEC Filings

    View All

    SEC Form 10-Q filed by Immunovant Inc.

    10-Q - Immunovant, Inc. (0001764013) (Filer)

    2/6/26 7:24:14 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Immunovant, Inc. (0001764013) (Filer)

    2/6/26 7:16:39 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Immunovant Inc.

    SCHEDULE 13D/A - Immunovant, Inc. (0001764013) (Subject)

    12/12/25 5:20:00 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    Financials

    Live finance-specific insights

    View All

    Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

    IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

    2/6/26 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

    DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,

    1/23/26 5:25:47 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

    Study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjögren's disease (SjD) remains on trackImmunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive dynamics, the Company anticipates sharing topline results from both TED studies concur

    11/10/25 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    Leadership Updates

    Live Leadership Updates

    View All

    Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

    Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

    9/23/24 8:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant Appoints Mark Levine as Chief Legal Officer

    Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil

    1/25/22 8:30:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant Appoints Renee Barnett as Chief Financial Officer

    Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen

    9/15/21 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunovant Inc.

    SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

    11/12/24 10:32:13 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

    SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

    2/14/24 8:47:41 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Immunovant Inc.

    SC 13G - Immunovant, Inc. (0001764013) (Subject)

    2/9/24 9:16:06 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care